The deal seeks to prevent Amgen from leveraging its near-monopoly on Tepezza and other Horizon drugs into an overwhelming competitive advantage.
Tag Archives: Krystexxa
Acquiring Tepezza and Krystexxa would give Amgen a monopoly on those treatments, which it could then use to smother competition, the FTC warns
More Top Stories
A federal judge has ordered Bard hernia mesh settlement negotiations to begin early next month, with the hopes of reaching a global resolution to the claims by late May.
A court-appointed mediator will update a U.S. District Judge on the status of Philips CPAP settlement negotiations for personal injury claims on Friday.
The U.S. JPML has ordered reservoir defect claims to be included in the Bard PowerPort lawsuit multidistrict litigation, over the manufacturers' objections.